TLDR
- Bernstein reiterates “outperform” on AZN with a £186 price target, implying ~37% upside from the £135.54 close
- Non-oncology is expected to drive ~65% of AstraZeneca’s projected 6% CAGR between 2026–2031, but investors are underpricing it
- Bernstein’s 2030 revenue forecast of $89.06B sits 11% above AstraZeneca’s own $80B guidance and 8% above Bloomberg consensus
- Key drug Wainua has a Bernstein 2035 estimate of $4.80B — 170% above Bloomberg consensus of $1.80B
- AZN rose 3.1% on June 4, bringing the price to $181.80; insiders sold $2.2M in the past three months with no buying
AstraZeneca (AZN) stock rose 3.1% on June 4, 2026, closing at $181.80. The stock trades in a 52-week range of $134.90 to $212.71.
Bernstein put out a note on Friday reiterating its “outperform” rating on AstraZeneca. The broker kept its price target at £186, against a closing price of £135.54 — that’s roughly 37% implied upside.
The core argument is simple: AstraZeneca’s non-oncology division isn’t getting the attention it deserves from investors.
Bernstein says this segment is expected to drive around 65% of the company’s projected 6% compound annual sales growth from 2026 to 2031. Yet analysts say it still doesn’t get “its fair share in the investment debate.”
The broker’s 2030 total revenue estimate sits at $89.06 billion. That’s 11% above AstraZeneca’s own risk-adjusted guidance of $80 billion and 8% above Bloomberg consensus of $82 billion. All projected top-line upside versus consensus between 2027 and 2035 is expected to come from non-oncology.
Wainua Stands Out
The biggest gap sits in Wainua, AstraZeneca’s drug for transthyretin amyloidosis (ATTR). Bernstein’s risk-adjusted 2035 estimate is $4.80 billion — 170% above Bloomberg consensus of $1.80 billion. AstraZeneca itself has guided to non-risk-adjusted peak sales of over $5 billion.
Phase 3 CARDIO-TTransform data is expected in the second half of 2026. AstraZeneca’s head of non-oncology R&D, Dr. Sharon Barr, noted that U.S. diagnosis rates for ATTR cardiomyopathy are still at just 30% — pointing to a large untapped patient pool.
Another drug getting attention is AZD0780, an oral PCSK9 inhibitor for high cholesterol. AstraZeneca has guided to peak sales of over $5 billion; Bloomberg consensus sits at $2.40 billion. Bernstein estimates $3.10 billion by 2035.
Dr. Barr also flagged that AZD0780 won’t carry fasting requirements — a potential edge over Merck’s competing candidate enlicitide decanoate.
COPD Drug Adds to the Case
Tozorakimab, AstraZeneca’s COPD drug, posted positive headline phase 3 data on March 27, 2026. AstraZeneca has guided peak sales of $3 billion to $5 billion against Bloomberg consensus of $2 billion.
In Bernstein’s bull case, it sees 179% upside to 2035 adjusted EBITA. Its bear case implies 101% downside.
The approved portfolio makes up 55% of the upside scenario. Ultomiris leads that group, with Bernstein’s 2035 estimate of $9.60 billion well above consensus of $6.50 billion.
On valuation, GuruFocus gives AZN a GF Score of 83/100. The current P/E of 27.3x sits below the five-year median of 34.2x. GF Value pegs the stock at $178.11 — slightly below the $181.80 price, flagging a modest 2.1% overvaluation.
One potential concern: insiders sold $2.2 million worth of stock over the last three months, with no buying activity reported.
Phase 3 CARDIO-TTransform data for Wainua remains the next key catalyst, expected in the second half of 2026.
🚨 Our MAY Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for May, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
